Novo Nordisk to restart liraglutide obesity studies (Reuters, 22 June 2010)
23 Jun 2010
Danish Pharma company Novo Nordisk has announced plans to restart trials of its type-2 diabetes drug liraglutide to assess its potential use as an anti-obesity medication.
